Cytopia zeroes in on brain
Monday, 17 November, 2008
Melbourne biotech Cytopia has commencing dosing patients in its Phase Ib/II trial of its vascular disrupting agent CYT997 in glioblastoma multiforme.
The trial will investigate the activity of CYT997 in combination with carboplatin and etoposide, common anti-cancer drugs.
CYT997 has been shown to ablate tumour blood vessels as well as inhibiting tubulin, thus affecting tumour cell replication. The compound is also being tested in multiple myeloma.
The trial will be held at Frankston Hospital in Victoria, with a second site in Sydney planned.
Scientists complete final chromosome in synthetic yeast genome
The synthetic chromosome includes features that enable researchers to generate genetic diversity...
Self-destructing vaccine protects against TB in monkeys
A self-destructing vaccine administered intravenously provides additional safety and protection...
New drug to prevent migraine claimed to work straight away
People taking atogepant showed improvement on assessments of how much migraine impaired their...
